This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
17 May 2019
In the original version of this article, the abbreviation CMAP was misspelt as CAMP. The spelling has been corrected in the HTML and PDF versions of the article.
References
Original article
Darras, B. T. et al. Nusinersin in later-onset spinal muscular atrophy. Long-term results from the phase ½ studies. Neurology https://doi.org/10.1212/WNL.0000000000007527 (2019)
Further reading
Groen, E. J. et al. Advances in therapy for spinal muscular atrophy: promises and challenges. Nat. Rev. Neurol. 14, 214–224 (2018)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fyfe, I. Long-term benefits of nusinersen in later-onset spinal muscular atrophy. Nat Rev Neurol 15, 368–369 (2019). https://doi.org/10.1038/s41582-019-0202-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-019-0202-4